Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Savanne Beekman"'
Autor:
Dylan Chapeau, Savanne Beekman, Maryana Handula, Erika Murce, Corrina de Ridder, Debra Stuurman, Yann Seimbille
Publikováno v:
EJNMMI Radiopharmacy and Chemistry, Vol 9, Iss 1, Pp 1-20 (2024)
Abstract Background Integrating radioactive and optical imaging techniques can facilitate the prognosis and surgical guidance for cancer patients. Using a single dual-labeled tracer ensures consistency in both imaging modalities. However, developing
Externí odkaz:
https://doaj.org/article/146801c7b094400b847694f41de23bd7
Autor:
Maryana Handula, Savanne Beekman, Mark Konijnenberg, Debra Stuurman, Corrina de Ridder, Frank Bruchertseifer, Alfred Morgenstern, Antonia Denkova, Erik de Blois, Yann Seimbille
Publikováno v:
EJNMMI Radiopharmacy and Chemistry, Vol 8, Iss 1, Pp 1-16 (2023)
Abstract Background The [177Lu]Lu-DOTA-TATE mediated peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors (NETs) is sometimes leading to treatment resistance and disease recurrence. An interesting alternative could be the somatostati
Externí odkaz:
https://doaj.org/article/b4c3e0284752465fa8ed5d7be031a77d
Autor:
Erika Murce, Evelien Spaan, Savanne Beekman, Lilian van den Brink, Maryana Handula, Debra Stuurman, Corrina de Ridder, Simone U. Dalm, Yann Seimbille
Publikováno v:
Pharmaceuticals, Vol 16, Iss 8, p 1072 (2023)
Small-molecule drug conjugates (SMDCs) are compounds in which a therapeutic payload is conjugated to a targeting vector, for specific delivery to the tumor site. This promising approach can be translated to the treatment of prostate cancer by selecti
Externí odkaz:
https://doaj.org/article/4423312b24fb4f2481115b99eb624897
Autor:
Dylan Chapeau, Sofia Koustoulidou, Maryana Handula, Savanne Beekman, Corrina de Ridder, Debra Stuurman, Erik de Blois, Yulia Buchatskaya, Karlijn van der Schilden, Marion de Jong, Mark W. Konijnenberg, Yann Seimbille
Publikováno v:
Pharmaceuticals, Vol 16, Iss 7, p 985 (2023)
Peptide receptor radionuclide therapy (PRRT) has been applied to the treatment of neuroendocrine tumors (NETs) for over two decades. However, improvement is still needed, and targeted alpha therapy (TAT) with alpha emitters such as lead-212 (212Pb) r
Externí odkaz:
https://doaj.org/article/b8faf153cecd468bae494dab626614f5
Autor:
Erika Murce, Stephen Ahenkorah, Savanne Beekman, Maryana Handula, Debra Stuurman, Corrina de Ridder, Frederik Cleeren, Yann Seimbille
Publikováno v:
Pharmaceuticals, Vol 16, Iss 6, p 882 (2023)
Bifunctional chelators (BFCs) are a key element in the design of radiopharmaceuticals. By selecting a BFC that efficiently complexes diagnostic and therapeutic radionuclides, a theranostic pair possessing almost similar biodistribution and pharmacoki
Externí odkaz:
https://doaj.org/article/f4b0bf3eefcc483bac911402c61e20c0
Autor:
Erika Murce, Savanne Beekman, Evelien Spaan, Maryana Handula, Debra Stuurman, Corrina de Ridder, Yann Seimbille
Publikováno v:
Molecules, Vol 28, Iss 10, p 4022 (2023)
Prostate-specific membrane antigen (PSMA) targeting radiopharmaceuticals have been successfully used for diagnosis and therapy of prostate cancer. Optimization of the available agents is desirable to improve tumor uptake and reduce side effects to no
Externí odkaz:
https://doaj.org/article/bd8475dd56774ac4a5e4e0245b3e0f3d
Autor:
Sofia Koustoulidou, Maryana Handula, Corrina de Ridder, Debra Stuurman, Savanne Beekman, Marion de Jong, Julie Nonnekens, Yann Seimbille
Publikováno v:
Pharmaceuticals, Vol 15, Iss 9, p 1155 (2022)
Somatostatin receptor subtype 2 (SSTR2) has become an essential target for radionuclide therapy of neuroendocrine tumors (NETs). JR11 was introduced as a promising antagonist peptide to target SSTR2. However, due to its rapid blood clearance, a bette
Externí odkaz:
https://doaj.org/article/8f079e48345642d6ae422b4ce72fbae7
Autor:
Seimbille, Dylan Chapeau, Sofia Koustoulidou, Maryana Handula, Savanne Beekman, Corrina de Ridder, Debra Stuurman, Erik de Blois, Yulia Buchatskaya, Karlijn van der Schilden, Marion de Jong, Mark W. Konijnenberg, Yann
Publikováno v:
Pharmaceuticals; Volume 16; Issue 7; Pages: 985
Peptide receptor radionuclide therapy (PRRT) has been applied to the treatment of neuroendocrine tumors (NETs) for over two decades. However, improvement is still needed, and targeted alpha therapy (TAT) with alpha emitters such as lead-212 (212Pb) r
Autor:
Seimbille, Erika Murce, Stephen Ahenkorah, Savanne Beekman, Maryana Handula, Debra Stuurman, Corrina de Ridder, Frederik Cleeren, Yann
Publikováno v:
Pharmaceuticals; Volume 16; Issue 6; Pages: 882
Bifunctional chelators (BFCs) are a key element in the design of radiopharmaceuticals. By selecting a BFC that efficiently complexes diagnostic and therapeutic radionuclides, a theranostic pair possessing almost similar biodistribution and pharmacoki